5PSQ-071 Efficacy and safety evaluation of trifluridine/tiparacil for metastatic colon cancer (mcrc)
Sabrina Herrera(Mayo Clinic), Coral García(Hospital Universitario Virgen de las Nieves), R. Fumero(Humanitas University), F Artime Rodríguez-Hermida(Hospital Universitario Virgen de las Nieves), Leyre Zúñiga(Hospital Universitario Virgen de las Nieves), S. Domínguez(Hospital Universitario Virgen de las Nieves), C Valencia Soto(Hospital La Inmaculada), A Jiménez Morales(Hospital Universitario Virgen de las Nieves)
Cited by 0
Related Papers
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
|Clinical Cancer Research|2015|119
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
|Breast Cancer Research and Treatment|2017|95
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase
|Breast Cancer Research|2014|70
Systematic Review of Microthrombi in COVID-19 Autopsies
|Acta Haematologica|2021|62
Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real‐world multicentre experience
|European Journal of Heart Failure|2022|62